Flow diagram by treatment groups. AraC, cytarabine arabinoside; CPX-351, liposomal formulation of AraC and daunorubicin at a fixed 5:1 molar ratio; FLYSYN trial (NCT02789254), therapy with Fc-optimized FLT3 antibody FLYSYN; HAM, high-dose AraC + mitoxantrone; ICE, idarubicin/AraC/etoposide; MICE, mitoxantrone/AraC/etoposide; PEMAZA trial (NCT03769532), combinational therapy of pembrolizumab and azacitidine; 7+3, intensive induction therapy with daunorubicin on days 1 to 3 plus AraC on days 1 to 7.